Robert Occhipinti, MD
Internal Medicine · New Orleans, LANPI 1023112679
Payments from drug & device makers
Across 249 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$640
- AbbVie$374
- Pfizer$371
- GSK$342
- Viiv Healthcare Company$320
- Novo Nordisk$315
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,485100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $640 |
| AbbVie(2 entities) | 17 | $374 |
| Pfizer | 20 | $371 |
| GSK | 20 | $342 |
| Viiv Healthcare Company | 15 | $320 |
| Novo Nordisk | 18 | $315 |
| Lilly USA, LLC | 18 | $311 |
| Merck | 19 | $287 |
| Amgen | 11 | $227 |
| Boehringer Ingelheim | 10 | $142 |
| Exact Sciences | 6 | $130 |
| Sanofi-aventis U.S. LLC | 8 | $118 |
| Theratechnologies Inc. | 5 | $116 |
| Gilead | 5 | $92 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Antares Pharma, Inc. | 4 | $73 |
| Dexcom, Inc. | 3 | $65 |
| Bayer | 3 | $58 |
| Kowa Pharmaceuticals America, Inc. | 3 | $49 |
| Abbott | 2 | $48 |
| Johnson & Johnson | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $36 |
| Astellas Pharma US Inc | 2 | $28 |
| Novartis | 2 | $28 |
| Mylan Specialty L.p. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$4,491 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 188 | $175,997 |
| MounjaroTirzepatide | 113 | $132,425 |
| JardianceEmpagliflozin | 96 | $129,182 |
| OzempicSemaglutide | 109 | $119,565 |
| JanuviaSitagliptin Phosphate | 94 | $89,138 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $55,369 |
| ProliaDenosumab | 25 | $42,751 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $35,583 |
| Repatha SureclickEvolocumab | 39 | $35,439 |
| TrulicityDulaglutide | 24 | $29,862 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $28,546 |
| EntrestoSacubitril/Valsartan | 25 | $21,420 |
| LinzessLinaclotide | 26 | $21,240 |
| XareltoRivaroxaban | 17 | $20,357 |
| FarxigaDapagliflozin Propanediol | 17 | $18,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $371 | $175,997188 claims |
| Lilly USA, LLCMounjaro, Trulicity | $311 | $162,286137 claims |
| Boehringer IngelheimJardiance, Tradjenta | $142 | $144,181118 claims |
| Novo NordiskOzempic | $315 | $119,565109 claims |
| MerckJanuvia | $287 | $89,13894 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $342 | $59,38192 claims |
| GileadBiktarvy | $92 | $55,36912 claims |
| AmgenProlia | $227 | $42,75125 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $640 | $32,97056 claims |
| AbbVieLinzess, Synthroid | $374 | $26,44473 claims |
| NovartisEntresto | $28 | $21,42025 claims |
| Johnson & JohnsonXarelto | $47 | $20,35717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in New Orleans
- William SmithNew Orleans$50.5M
- Brian LewisNew Orleans$2M
- Steven DeitelzweigNew Orleans$939K
- Lydia BazzanoNew Orleans$892K
- Eboni Price-HaywoodNew Orleans$659K
- Susan Lewis AbdalianNew Orleans$301K
- Eduardo RodriguezNew Orleans$167K
- Shigeki SaitoNew Orleans$120K
- Jonathan GugelNew Orleans$95K
- Keith WinfreyNew Orleans$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.